Stakeholders Must ‘Fully Engage’ If WHO’s Medicines Access Platform Is To Succeed
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”
You may also be interested in...
WHO Medicines Access Platform ‘Compromised’ By Industry Involvement
A new World Health Organization platform for discussing access to medicines could be too heavily influenced by the pharmaceutical industry, says the NGO Health Action International. The European industry federation EFPIA disagrees.
New WHO Access Platform Could Mean Tiered Pricing In Europe
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.